Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis
Shots:
- Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU- with 45 days to exercise the option on basis of its P-IIb results
- If Almirall exercises its option- Dermira will receive $50M as option exercise fee- $30M milestones on the onset of P-III trial- $85M as regulatory milestone and on first sale in EU- and threshold milestones & royalties on net sales of lebrikizumab in EU
- Lebrikizumab is a mAb- bind to IL-13- involved in prevention of the formation of IL-13Rα1/IL-4Rα heterodimer complex and is evaluated in P-IIb study in 280 patients with moderate-to-severe atopic dermatitis aged >18yrs.
Ref: Globe Newswire | Image: Pharmaphorum
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com